tbuckley/cabot-search huggingface dataset:
Towards an artificial human lung: modelling organ-like complexity to aid mechanistic understanding
Authors: Maria Victoria Humbert, Cosma Mirella Spalluto, Joseph Bell, Cornelia Blume, Franco Conforti, Elizabeth R. Davies, Lareb S.N. Dean, Paul Elkington, Hans Michael Haitchi, Claire Jackson, Mark G. Jones, Matthew Loxham, Jane S. Lucas, Hywel Morgan, Marta Polak, Karl J. Staples, Emily J. Swindle, Liku Tezera, Alastair Watson, Tom M.A. Wilkinson
Journal: European Respiratory Journal (2022)

Respiratory diseases account for over 5 million deaths yearly and are a huge burden to healthcare systems worldwide. Murine models have been of paramount importance to decode human lung biology in vivo , but their genetic, anatomical, physiological and immunological differences with humans significantly hamper successful translation of research into clinical practice. Thus, to clearly understand human lung physiology, development, homeostasis and mechanistic dysregulation that may lead to disease, it is essential to develop models that accurately recreate the extraordinary complexity of the human pulmonary architecture and biology. Recent advances in micro-engineering technology and tissue engineering have allowed the development of more sophisticated models intending to bridge the gap between the native lung and its replicates in vitro . Alongside advanced culture techniques, remarkable technological growth in downstream analyses has significantly increased the predictive power of human biology-based in vitro models by allowing capture and quantification of complex signals. Refined integrated multi-omics readouts could lead to an acceleration of the translational pipeline from in vitro experimental settings to drug development and clinical testing in the future. This review highlights the range and complexity of state-of-the-art lung models for different areas of the respiratory system, from nasal to large airways, small airways and alveoli, with consideration of various aspects of disease states and their potential applications, including pre-clinical drug testing. We explore how development of optimised physiologically relevant in vitro human lung models could accelerate the identification of novel therapeutics with increased potential to translate successfully from the bench to the patient's bedside.
P-301 Pre-surgical carcinoembryonic antigen as a recurrence biomarker in stage III colon cancer treated with adjuvant chemotherapy in a Latin American center
Authors: E. Veramendi Cabana, J. Cotito Izquierdo, J. Macetas, F. Serrano, C. Pacheco-Román, V. Castro, J. Araujo, P. Montenegro
Journal: Annals of Oncology (2022)
P-161 Trial in progress: Neoadjuvant combination therapy of lenvatinib plus transcatheter arterial chemoembolization (TACE) for transplant-eligible patients with large hepatocellular carcinoma
Authors: M. Abdelrahim, A. Esmail, A. Saharia, S. Kodali, D. Victor, K. Heyne, R. Ghobrial
Journal: Annals of Oncology (2022)
SO-33 Neoadjuvant immunotherapy in gastrointestinal tumors with mismatch repair deficiency: An institutional analysis
Authors: S. Chakrabarti, M. Parish, A. Ruggeri, A. Shreenivas, M. Kamgar, D. Sriram, C. Peterson, T. Ridolfi, K. Ludwig, A. Alqwasmi, C. Mooney, J. Burfeind, C. Clarke, K. Christians, T. Gamblin, B. George, J. Thomas
Journal: Annals of Oncology (2022)
P-126 Clustering analysis identified three IDH1-mutated intrahepatic cholangiocarcinoma's clusters with prognostic significance
Authors: M. Rimini, E. Loi, C. Fabregat, V. Burgio, S. Lonardi, M. Niger, M. Scartozzi, I. Rapposelli, G. Aprile, F. Ratti, F. Pedica, T. Macarulla, F. De Cobelli, L. Aldrighetti, L. Fornaro, S. Cascinu, P. Zavattari, A. Casadei-Gardini
Journal: Annals of Oncology (2022)
Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally
Authors: Tiziana Masini, Avinash Kanchar, Fuad Mirzayev, Kerri Viney, Askar Yedilbayev, Matteo Zignol, Dennis Falzon
Journal: European Respiratory Journal (2022)

In their correspondence, L. Guglielmetti et al. emphasize the importance of improved access to rifapentine globally, both for the treatment of tuberculosis (TB) disease as well as part of TB preventive treatment (TPT) regimens. They also highlight some of the major problems with access to this medicine, especially in the European Union (EU) [1], foremost amongst which being the absence of market authorization of rifapentine in the EU. In this letter we highlight key actions taken by the World Health Organization (WHO) to address important barriers to the implementation of recommendations on rifapentine. Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of Interest: All authors have nothing to disclose.
P-130 Latin American population with adenocarcinoma of the esophagogastric junction: A 9-year follow up
Authors: G. Calderillo-Ruiz, M. Herrera, A. Takahashi, C. Diaz, E. Ruiz-Garcia, H. Lopez Basave, B. Carbajal-López, A. Albarran, M. García-Gámez
Journal: Annals of Oncology (2022)
P-167 Identification of peptides inhibitor clade A member 1 as a novel serum biomarker for gastric cancer and promotes liver metastasis
Authors: W. Li, R. Tan, Z. Yang
Journal: Annals of Oncology (2022)

Approximately 9. 9%~18. 7% of gastric cancer (GC) patients experience liver metastasis (LM) during the course of the disease and is highly associated with poor prognosis. The development of sensitive biomarkers for detecting and predicting liver metastasis is required for a better clinical outcome. Serpin peptidase inhibitor clade A member 1 (SERPINA1) has been studied in several types of cancer; However, their functional in gastric cancer remains unknown. The present study aimed to evaluate SERPINA1 as a novel serum prognostic biomarker for gastric cancer and associated with liver metastasis. A retrospective cohort with 68 surgically resected gastric cancer patients and a prospective cohort with 45 gastric cancer patients with liver metastasis from The Sixth Affiliated Hospital of Sun Yat-sen University were constructed. Immunohistochemistry was performed to evaluate expression of SERPINA1 protein in tissue specimens. Enzyme-linked immunosorbent assays (ELISAs) were used to analyze the serum specimens. Detailed clinicopathological parameters as well as patients' survival were recorded. A nomogram including SERPINA1 expression was also constructed and validated to predict the prognosis of gastric cancer patients. SERPINA1 protein expression was also analyzed by western blot in human GC derived cell lines and a normal epithelial cell line. Functional experiments were performed by overexpression and downregulation of SERPINA1 in GC derived cell lines and a normal epithelial cell line. Serum SERPINA1 expression was obviously increased and associated with tumor stage in gastric cancer patients, and its high expression was significantly related to differentiated phenotype and vessel invasion, as well as liver metastasis. High SERPINA1 expression was significantly associated with hepatic recurrence after curative surgery, and cumulative incidences of hepatic recurrence were significantly greater in patients with high SERPINA1 expression compared with patients with low SERPINA1 expression. High SERPINA1 expression indicated a poor prognosis, and monogram including serum SERPINA1 expression could predict the prognosis of gastric cancer patients effectively. Moreover, serum ITGB6 expression was associated with ITGB6 expression in tumor tissues. On the other hand, SERPINA1 showed differential expression GC cell lines. By using western blotting, wound-healing and invasion assays in cell lines, overexpression of SERPINA1 increased the migration and invasion of gastric cancer cells, whereas knockdown of SERPINA1 decreased these functions. Moreover, SERPINA1 overexpression increased the protein levels of VEGFR2, which is a key regulator of the VEGF signaling pathway. The present study identified that SERPINA1 could serve as a novel serum biomarker for the risk stratification, prognostic prediction of gastric cancer patients and is also related to liver metastasis.
Reopenable-clip band-assisted underwater endoscopic mucosal resection to obtain a large specimen
Authors: Tatsuma Nomura, Haruka Nakamura, Shinya Sugimoto, Jun Oyamada, Keiichi Ito, Akira Kamei, Yoshikazu Hayashi
Journal: Endoscopy (2022)

Although en bloc resection of colorectal tumors larger than 20 mm is challenging for snare resection [1] [2], it should be pursued because piecemeal resection causes local recurrence afterward. Even when a large snare is used, the entire lesion is not captured when the snare tip slips forward and the snare does not open wide. Although some methods for fixing a snare tip at the proximal mucosa have been reported, they are not always effective [3] [4]. We devised a reopenable-clip band-assisted technique for underwater endoscopic mucosal resection (RB-UEMR) using a 35-mm snare to fix the snare tip to enable removal of a tumor as a large single specimen.
SO-20 Stanniocalcin 1 (STC1) in patients with refractory colorectal cancer (CRC) treated with regorafenib: An exploratory analysis of the CORRECT trial
Authors: A. Vienot, D. Vernerey, A. Bouard, E. Klajer, K. Asgarov, S. Kim, C. Tournigand, C. Louvet, T. André, B. Rousseau, M. Wespiser, Y. Wang, A. Schulz, E. Dochy, C. Borg
Journal: Annals of Oncology (2022)

We previously described a prognostic role for the glycoprotein STC1 in patients with metastatic CRC (mCRC) receiving first-line chemotherapy and in a small number of patients with refractory mCRC previously treated with regorafenib (Jary, et al. Int J Cancer 2020). Regorafenib is approved for the treatment of patients with mCRC based an improvement in overall survival (OS) in the placebo-controlled, randomized, phase 3 CORRECT trial (Grothey, et al. Lancet 2013; NCT01103323). Here, we investigate the relationship between STC1 and clinical outcome in patients from CORRECT. In this exploratory analysis, STC1 protein levels were measured by ELISA in plasma samples collected at baseline. The relationship between STC1 levels and OS was evaluated using a Cox proportional hazards model. Of 679 patients with available plasma samples, STC1 levels were evaluable in 646 patients (placebo n=211; regorafenib n=435). The baseline characteristics of the biomarker cohort were similar to the overall cohort. The overall median STC1 value was 1203 pg/mL (range: 320–6568). STC1 levels were comparable between the regorafenib (median: 1181 pg/mL; range: 375–6568) and placebo (median: 1232 pg/mL; range: 320–6223) cohorts. The cutoff for the prognostic effect was optimized based on a Cox model for OS combining both regorafenib and placebo arms. Patients with STC1 levels at 1437 pg/mL or higher (n=246) had a median OS of 3.81 months (95% CI 3.45–4.47) versus 7.63 months (95% CI 7.04–8.45) for patients with levels below 1437 pg/mL (n=400). The prognostic value of STC1 levels at baseline was significant in patients included in both the placebo group (HR 2.69, 95% CI 1.99–3.63; p < 0.001) and in the regorafenib group (HR 1.90, 95% CI 1.55–2.32; p < 0.001). We next assessed if STC1 levels could predict regorafenib efficacy. The optimized cutoff for the prognostic effect was used to assess the predictive effect of regorafenib versus placebo on OS. In the presence of high levels of STC1, OS was improved with regorafenib (median OS: 4.41 months, 95% CI 3.75–5.19) versus placebo (median OS: 3.09 months, 95% CI 2.56–3.91; p=0.001). The interaction p-value between STC1 levels and treatment for OS was 0.044 (STC1 high: HR 0.64, 95% CI 0.49–0.84; STC1 low: HR 0.83, 95% CI 0.66–1.03). We identified STC1 as a prognostic marker in patients with refractory mCRC. High STC1 protein levels characterized a population of patients with poor prognosis who benefit most from treatment with regorafenib.
Warthog Genomes Resolve an Evolutionary Conundrum and Reveal Introgression of Disease Resistance Genes
Authors: Genís Garcia-Erill, Christian H F Jørgensen, Vincent B Muwanika, Xi Wang, Malthe S Rasmussen, Yvonne A de Jong, Philippe Gaubert, Ayodeji Olayemi, Jordi Salmona, Thomas M Butynski, Laura D Bertola, Hans R Siegismund, Anders Albrechtsen, Rasmus Heller
Journal: Molecular Biology and Evolution (2022)

Abstract African wild pigs have a contentious evolutionary and biogeographic history. Until recently, desert warthog (Phacochoerus aethiopicus) and common warthog (P. africanus) were considered a single species. Molecular evidence surprisingly suggested they diverged at least 4.4 million years ago, and possibly outside of Africa. We sequenced the first whole-genomes of four desert warthogs and 35 common warthogs from throughout their range. We show that these two species diverged much later than previously estimated, 400,000–1,700,000 years ago depending on assumptions of gene flow. This brings it into agreement with the paleontological record. We found that the common warthog originated in western Africa and subsequently colonized eastern and southern Africa. During this range expansion, the common warthog interbred with the desert warthog, presumably in eastern Africa, underlining this region’s importance in African biogeography. We found that immune system–related genes may have adaptively introgressed into common warthogs, indicating that resistance to novel diseases was one of the most potent drivers of evolution as common warthogs expanded their range. Hence, we solve some of the key controversies surrounding warthog evolution and reveal a complex evolutionary history involving range expansion, introgression, and adaptation to new diseases.
P-49 GOBLET: A phase 1/2 multiple indication signal finding and biomarker study in advanced gastrointestinal cancers treated with pelareorep and atezolizumab – safety and preliminary response results
Authors: M. Collienne, D. Arnold, A. Stein, E. Goekkurt, U. Martens, H. Loghmani, T. Heineman
Journal: Annals of Oncology (2022)
P-125 Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)
Authors: A. Hendifar, L. Rosen, A. McRee, A. Cercek, A. Basu-Mallick, D. Spigel, S. Tavazoie, E. Rowinsky, M. Szarek, F. Gonsalves, I. Kurth, C. Andreu, R. Busby, S. Spector, D. Darst, N. Lebaka, N. Bechar, M. Tavazoie, R. Wasserman, M. Fakih
Journal: Annals of Oncology (2022)
PD-5 IDH1 in intrahepatic cholangiocarcinoma: A comparative genomic analysis and clinical impact
Authors: M. Rimini, C. Fabregat, V. Burgio, S. Lonardi, M. Niger, M. Scartozzi, I. Rapposelli, G. Aprile, F. Ratti, F. Pedica, T. Macarulla, M. Fassan, A. Pretta, F. Simionato, F. De Cobelli, L. Aldrighetti, L. Fornaro, S. Cascinu, A. Casadei Gardini
Journal: Annals of Oncology (2022)
P-12 A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
Authors: T. André, E. Van Cutsem, E. Elez, J. Bennouna, C. de la Fouchardière, T. Yoshino, L. Jensen, G. Mendez, J. Li, E. Goekkurt, S. Abdullaev, T. Chen, M. Lei, S. Lonardi
Journal: Annals of Oncology (2022)
P-87 Clinical score to predict recurrence in patients with stage II and III colon cancer
Authors: D. Viñal, S. Martinez-Recio, D. Martinez Perez, D. Jimenez-Bou, I. Ruiz, J. Peña, G. Martin-Montalvo, M. Alameda, A. Rueda-Lara, L. Gutierrez-Sainz, M. Palacios, A. Custodio, I. Ghanem, J. Feliu, N. Rodríguez-Salas
Journal: Annals of Oncology (2022)
A Mapping Review of Real-Time Movement Sonification Systems for Movement Rehabilitation
Authors: Thomas H. Nown, Priti Upadhyay, Andrew Kerr, Ivan Andonovic, Christos Tachtatzis, Madeleine A. Grealy
Journal: IEEE Reviews in Biomedical Engineering (2022)

Movement sonification is emerging as a useful tool for rehabilitation, with increasing evidence in support of its use. To create such a system requires component considerations outside of typical sonification design choices, such as the dimension of movement to sonify, section of anatomy to track, and methodology of motion capture. This review takes this emerging and highly diverse area of literature and keyword-code existing real-time movement sonification systems, to analyze and highlight current trends in these design choices, as such providing an overview of existing systems. A combination of snowballing through relevant existing reviews and a systematic search of multiple databases were utilized to obtain a list of projects for data extraction. The review categorizes systems into three sections: identifying the link between physical dimension to auditory dimension used in sonification, identifying the target anatomy tracked, identifying the movement tracking system used to monitor the target anatomy. The review proceeds to analyze the systematic mapping of the literature and provide results of the data analysis highlighting common and innovative design choices used, irrespective of application, before discussing the findings in the context of movement rehabilitation. A database containing the mapped keywords assigned to each project are submitted with this review.
P-73 Survival outcomes of surgical resection in perihilar cholangiocarcinoma in endemic area of O. Viverrini, Thailand
Authors: P. Sarkhampee, A. Tantraworasin, P. Sririchidakul, S. Junrungsee, P. Wattanarath, S. Chansitthichok, N. Lertsawatvicha, W. Ouransatien
Journal: Annals of Oncology (2022)
P-171 Prognostic value of conversion from RAS-mutated to RAS wild-type during treatment of metastatic colorectal cancer using liquid biopsies – real-world data of two Portuguese institutions
Authors: J. Albuquerque, D. Neto da Silva, T. Padrão, L. Leal da Costa, R. Bizarro, J. Correia, C. Baptista, M. Machete, G. Prazeres, I. Margarido, G. Fernandes, P. Simões, T. Timóteo, F. Lopes, J. Godinho, J. Moreira-Pinto, T. Rodrigues, A. Faria, C. Pulido, L. Cirnes, J. Teixeira, J. Passos-Coelho
Journal: Annals of Oncology (2022)
P-23 Phase II study (daNIS-3) of the anti–TGF-β monoclonal antibody NIS793 and other new investigational drug combinations with standard-of-care therapy vs standard-of-care alone in patients with second-line metastatic colorectal cancer
Authors: N. Segal, F. Rivera, C. Tournigand, S. Kasper, Y. Chen, P. Deshpande, R. Messmann, S. Kopetz
Journal: Annals of Oncology (2022)
Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open‐label, randomized controlled trial
Authors: Alberto Domínguez‐Rodríguez, Coral Suero‐Mendez, Guillermo Burillo‐Putze, Victor Gil, Rafael Calvo‐Rodriguez, Pascual Piñera‐Salmeron, Pere Llorens, Francisco J. Martín‐Sánchez, Pedro Abreu‐Gonzalez, Òscar Miró
Journal: European Journal of Heart Failure (2022)
PD-6 DNA methylome as a potential biomarker in biliary brushes and bile fluid samples to differentiate between benign and malignant biliary stenosis
Authors: S. Cappuyns, T. Venken, S. Stoffels, G. Philips, W. Laleman, S. van der Merwe, H. van Malenstein, D. Lambrechts, J. Dekervel
Journal: Annals of Oncology (2022)
P-257 In vitro drug screening of patient-derived 3D tumoroids replicates resistance to FOLFOX, FOLFIRI, and FOLFOXIRI in clinically resistant patients with metastatic colorectal cancer
Authors: G. Hagel, O. Thastrup, S. Rafaelsen, J. Thastrup, J. Lindebjerg
Journal: Annals of Oncology (2022)
PD-14 Resectability, conversion, and resection rates with survival according to RAS and BRAF mutations in a prospective metastatic colorectal cancer study (liver-limited subgroup in the RAXO study)
Authors: A. Uutela, T. Salminen, E. Osterlund, J. Kononen, R. Kallio, K. Lehtomäki, A. Ålgars, A. Lamminmäki, P. Halonen, R. Ristamäki, L. Soveri, H. Stedt, E. Heervä, A. Nordin, A. Ristimäki, S. Kytölä, T. Kuopio, M. Mäkinen, L. Nieminen, J. Sundström, H. Isoniemi, P. Osterlund
Journal: Annals of Oncology (2022)
P-214 Efficacy and safety of anti-PD-1 agents in patients with dMMR metastatic solid tumours: A retrospective, real-world study
Authors: E. Terán Brage, R. Vidal Tocino, Á Moreno Gómez, L. Figuero Pérez, Á López Gutiérrez, R. Lozano Mejorada, E. Fonseca Sánchez
Journal: Annals of Oncology (2022)
P-152 Real-world data in patients with localized esophageal and gastro-esophageal junction cancer undergoing surgery in France: Results from the FREGAT database
Authors: G. Piessen, A. Adenis, F. Renaud, S. Devaux, P. Singh, H. Xiao, P. Casabianca, C. Jamain, C. Emery, E. Torreton, F. Fagnani
Journal: Annals of Oncology (2022)
P-122 Vitamin D-based score in gastric cancer
Authors: A. Cousillas Castiñeiras, E. Gallardo Martin, A. Fernández Montes, M. Covela-Rúa, N. Martínez-Lago, M. Salgado Fernandez, M. Pellón Augusto, P. Gonzalez Villarroel, J. de la Cámara Gómez, E. Brozos Vázquez, F. Vázquez-Rivera, J. Méndez Méndez
Journal: Annals of Oncology (2022)
P-48 Phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: Cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer
Authors: A. Naing, H. Mamdani, M. Barve, M. Johnson, R. Wolff, D. Kim, S. Yang, B. Lee, T. Adebanjo, R. Georgevitch, S. Ferrando-Martinez, C. Haymaker, M. Chaney, J. Fan, R. Kim, S. Pant
Journal: Annals of Oncology (2022)
P-57 An observational/translational study of BRAF inhibitor combination therapy for BRAF-mutant metastatic colorectal cancer including biomarker research: BEETS trial (JACCRO CC-18)
Authors: Y. Sunakawa, C. Inagaki, S. Yuki, M. Shiozawa, A. Tsuji, R. Matoba, E. Inoue, K. Muro, W. Ichikawa
Journal: Annals of Oncology (2022)
P-99 A multicenter phase II study of mFOLFOX6 in advanced gastric cancer patients with severe peritoneal metastases: WJOG10517G
Authors: H. Hara, T. Masuishi, T. Ando, T. Kawakami, Y. Yamamoto, N. Sugimoto, K. Shiraishi, T. Esaki, Y. Negoro, T. Tsuzuki, H. Sawai, M. Nakamura, T. Inagaki, Y. Shinohara, H. Kawakami, K. Kawakami, H. Katsuya, O. Maeda, Y. Fujita, K. Yoshimura, T. Nakajima, K. Muro
Journal: Annals of Oncology (2022)
PD-12 Characterization of best responder patients to oxaliplatin rechallenge in patients with refractory metastatic colorectal cancer (mCRC)
Authors: F. Salva, A. Garcia, N. Saoudi, I. Baraibar, J. Ros, R. Comas, F. Ruiz, A. Rezqallah, J. Cuadra, R. Dientsmann, J. Tabernero, E. Elez
Journal: Annals of Oncology (2022)
P-41 What to expect from best supportive care as initial approach for newly-diagnosed colorectal cancer: A single institution experience
Authors: D. Viñal, S. Martinez-Recio, D. Martinez Perez, I. Ruiz, J. Peña, D. Jimenez-Bou, A. Rueda-Lara, G. Martin-Montalvo, M. Alameda, M. Palacios, A. Custodio, L. Gutierrez-Sainz, I. Ghanem, J. Feliu, N. Rodríguez-Salas
Journal: Annals of Oncology (2022)
P-113 A multicenter observational study of liposomal irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON-2): Retrospective part
Authors: T. Imajima, T. Shirakawa, M. Shimokawa, T. Otsuka, T. Shibuki, J. Nakazawa, S. Arima, K. Miwa, Y. Okabe, F. Koga, Y. Kubotsu, Y. Ueda, A. Hosokawa, S. Takeshita, H. Shimokawa, A. Komori, M. Kawahira, H. Oda, K. Sakai, S. Arita, T. Mizuta, K. Mitsugi
Journal: Annals of Oncology (2022)
P-16 PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine + cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement
Authors: G. Abou-Alfa, I. Borbath, L. Goyal, A. Lamarca, T. Macarulla, D. Oh, S. Roychowdhury, S. Sadeghi, R. Shroff, J. Soto, G. Pedrioli, L. Fumagalli, C. Dambkowski, M. Javle
Journal: Annals of Oncology (2022)